Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer

Sponsor
Peking Union Medical College Hospital
Study ID
NCT04068974
Phase
PHASE2
Status
Unknown

Conditions

  • Recurrent Platinum-resistant Ovarian Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab (SHR-1210) — DRUG
    Anticancer T-cell activity is regulated by multiple suppressive mechanisms, including tumour-expressed programmed cell death ligand 1 (PD-L1) signalling to the T-cell inhibitory receptor (programmed death protein 1 \[PD-1\]). Monoclonal antibodies like SHR-1210 that can block this pathway.
  • Apatinib — DRUG
    Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2.

Study Details

This study is intend to improve the progression-free survial of the recurrent paltinum-resistant ovarian cancer. All the participants will receive camrelizumab combined with apatinib.

Key Dates

Start date
Oct 28, 2019
Status verified
Mar 2021
Primary completion
Jun 30, 2021
Completion
Jun 30, 2022

Study Design

Enrollment
28 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Test group
    Camrelizumab (SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle. Apatinib :250 mg po qd

Primary Outcome Measure

Objective Response Rate [ Time Frame: Up to two years ]

Central Contacts